此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

脑动静脉畸形伴动脉瘤:流行病学、临床特征与预后

2026年11月10日 更新者:Duan Chuanzhi

脑动静脉畸形和颅内动脉瘤患者的血流动力学机制、临床特征及预后因素:一项观察性队列研究

The study is a multicenter, prospective cohort study designed to assess the natural history, clinical safety and efficacy of various treatment strategies in patients with cerebral arteriovenous malformations (AVMs) and intracranial aneurysms.

研究概览

详细说明

This study aims to evaluate the clinical safety and efficacy of different treatment strategies in patients with cerebral arteriovenous malformations (AVMs) combined with intracranial aneurysms (IAs) through a multicenter, large-sample, prospective observational cohort study. It will comprehensively analyze the epidemiological characteristics, clinical manifestations, associated risk factors, natural disease progression, and bleeding risks, as well as explore the hemodynamic mechanisms and genetic background differences. Clinical data, imaging findings, and blood samples will be collected from patients to investigate the impact of hemodynamics on aneurysm formation, rupture risk, and treatment outcomes. Additionally, the study will explore the genetic differences of AVM and IA patients and their correlation with clinical presentation and prognosis, ultimately providing a scientific basis for individualized treatment strategies.

研究类型

观察性的

注册 (估计的)

630

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Guangdong
      • Guangzhou、Guangdong、中国、528400
        • 招聘中
        • Zhujiang Hospital, Southern Medical University
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人
  • 年长者

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Patients treated across eight neurosurgery centers who were confirmed by digital subtraction angiography (DSA), and/or magnetic resonance imaging (MRI), computed tomographic angiography (CTA) to have cerebral arteriovenous malformation and intracranial aneurysm.

描述

Inclusion Criteria:

  • Patients diagnosed with cerebral arteriovenous malformation and intracranial aneurysm confirmed by CTA, MRA, and/or DSA;
  • Availability of complete clinical and imaging data;
  • Provision of written informed consent by the patient or their legally authorized representative to participate in the study and undergo follow-up;
  • Not concurrently participating in any other clinical trials that may interfere with the outcomes of this study.

Exclusion Criteria:

  • Previous complete occlusion of the aneurysm and/or arteriovenous malformation prior to enrollment;
  • Coexistence of other cerebrovascular diseases such as moyamoya disease, cerebral cavernous malformation, cerebral venous sinus thrombosis, etc.;
  • Absence of DSA imaging data or poor image quality that precludes accurate evaluation of key anatomical and hemodynamic parameters of the AVM and intracranial aneurysm.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
Patients diagnosed with cerebral arteriovenous malformations and intracranial aneurysms

Patients diagnosed with concomitant cerebral arteriovenous malformations and intracranial aneurysms by digital subtraction angiography (DSA), and/or magnetic resonance imaging (MRI), and/or computed tomographic angiography (CTA).

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Imaging Treatment Success Rate of Target Vascular Lesions
大体时间:3 months postoperatively, 6 months postoperatively, 1years postoperatively, and 2 years postoperatively

his is a composite endpoint with stratified reporting by lesion type. It will separately calculate and report the success rates for the following two patient cohorts:

For patients with intracranial aneurysms: Treatment success is defined as complete occlusion on postoperative digital subtraction angiography, assessed as Class I by the Raymond-Roy Occlusion Classification (RROC) or as Grade D by the O'Kelly-Marotta (OKM) grading scale.

For patients with cerebral arteriovenous malformations (AVMs): Treatment success is defined as complete embolization on postoperative digital subtraction angiography, confirmed by the core laboratory or two independent assessors with no residual nidus opacification.

Critical clarification: This composite measure does NOT calculate an overall arithmetic combined success rate. The final reported values will be two independent percentages.

3 months postoperatively, 6 months postoperatively, 1years postoperatively, and 2 years postoperatively

次要结果测量

结果测量
措施说明
大体时间
Incidence of perioperative complications
大体时间:Perioperative period

Perioperative complications include technical related complications (vascular rupture, thrombosis, etc.) and clinical complications (neurological deficits, infections, etc.)

Perioperative period
Proportion of patients with hemorrhagic complications during follow-up period
大体时间:within three years

Including the type of bleeding (intracerebral hemorrhage/subarachnoid hemorrhage/intraventricular hemorrhage), specific location of bleeding,amount of bleeding;and determination of bleeding source: determine the source of bleeding from malformation or aneurysm through imaging examination.

within three years
Proportion of patients with poor functional prognosis
大体时间:3 months postoperatively, 6 months postoperatively,and one year postoperatively

mRS score 3-6

3 months postoperatively, 6 months postoperatively,and one year postoperatively
Proportion of patients with good functional prognosis
大体时间:3 months postoperatively, 6 months postoperatively,and one year postoperatively

mRS score 0-2

3 months postoperatively, 6 months postoperatively,and one year postoperatively

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年1月1日

初级完成 (估计的)

2030年11月30日

研究完成 (估计的)

2030年12月30日

研究注册日期

首次提交

2025年12月8日

首先提交符合 QC 标准的

2026年1月17日

首次发布 (实际的)

2026年1月20日

研究记录更新

最后更新发布 (实际的)

2026年11月16日

上次提交的符合 QC 标准的更新

2026年11月10日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅